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Introduction
Tendon or ligament injuries are the common causes 
of orthopedic disorders in active horses (Equus ferus 
caballus) of any age and breed (Thorpe et al., 2010). 
According to statistics, injuries amount to 86% of all 
diseases, whereas 37% are due to the pathology of 
muscles, tendons, and joints in sports horses. These 
injuries may involve a long recovery course, which can 
last up to 9–12 months (O’Meara et al., 2010). Injuries 
to the tendon-ligamentous apparatus cause the horses 
to lose their working capacity and are released from 
work for as long as they do not recover. Moreover, the 
injuries lead to chronic diseases in the musculoskeletal 
system, which are manifested by the destructive-
dystrophic damage to collagen fibers of tendons, as 
well as adjacent and underlying tissues (Nogteva et 
al., 2012; Vlasov et al., 2015). Most sick horses (up to 
80%) with micro- and macro-tendon ruptures suffered 
from repeated injuries after 3–12 months following 
their initial injuries (Dowling et al., 2000).
The main causes of horse tendon injuries are: sudden 
tendon extension with a sharp contraction of muscles, 
an early high level of physical activities, and tendon 
hyperthermia (Dyson, 2004; Kovac, 2013). Tendonitis 
is characterized by microtrauma, rupture of tendon 
fibers and fibrils, and intracranial microcirculation, 
leading to the death of tenocytes and the development 
of aseptic inflammatory processes (Dahlgren, 2005; 
Smith et al., 2014). The long healing process occurs 
due to hypovascularity in combination with tendon 
hypocellularity. Scarring after damage to the tendons 
can cause a rupture in the tendons of a predisposed 
horse and may occur due to increased expression of 
collagen type III (COL3), which has less fiber and 
less crosslinking compared to collagen type I (COL1), 
which leads to a deterioration in its mechanical 
properties (Patterson-Kane et al., 2012; O’Brien and 
Smith, 2018).
Currently, recombinant proteins and gene therapy 
are the most emerging advanced therapeutic methods 
used in the treatment of the different musculoskeletal 
problems in both human (Martinek et al., 2005) 
and veterinary medicines. The aim of this study is 
to evaluate the therapeutic efficacy of gene therapy 
plasmid DNA (pDNA) containing species-specific 
vascular endothelial growth factor (VEGF164) and 
fibroblast growth factor 2 (FGF2) coding sequences for 
the treatment of severely damaged superficial digital 
flexor tendons of the horse.
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Abstract
Background: Tendon injuries are one of the most common causes of orthopedic disorders in horses. Such injuries 
involve a long course of treatment and recovery. The most promising method of treating these injuries is the use of 
recombinant proteins and gene therapy.
Aim: In this work, we evaluated the therapeutic efficacy of plasmid DNA (pDNA) containing two species-specific 
coding sequences, i.e. vascular endothelial growth factor 164 (VEGF164) and fibroblast growth factor 2 (FGF2), in the 
treatment of severe damage to the tendon of the superficial digital flexor. 
Methods: A pDNA construct was used to restore the damaged superficial digital flexor tendon in the horse. 
Results: This study showed that the administration of pDNA encoding VEGF164 and FGF2 genes at the injury area 
increased the regenerative activities of the damaged tendon.
Conclusion: This study shows the therapeutic properties of genetic constructs (pDNA) and contributes to the 
advancements in the use of these therapies.
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Materials and Methods
Plasmid DNA
In this study, we used pDNA containing coding 
sequences of species-specific VEGF164 and FGF2 
genes used in our previous case report (Litvin et al., 
2016).  The pDNA in this study was a genetic construct 
(named pBUDK-ecVEGF164-ecFGF2) developed 
to repair and restore damaged connective tissues in 
tendons and ligaments. The recombinant plasmid 
contained one of the coding sequences from the VEGF 
and FGF proteins growth factor families (E. caballus 
VEGF164 and FGF2, respectively). Also, the use of 
the construct pBUDK-ecVEGF164-ecFGF2 pDNA 
was reported previously (Litvin et al., 2016). The 
dosage of the pDNA was checked on the agarose gel 
electrophoresis, the resultant sterile drug contained 
≥95% pDNA in a supercoiled form and the endotoxin 
content was ≤ 0.03 EU/mg pDNA in lyophilized form 
(aliquoted in doses of 5 mg).
Preparation and introduction of plasmid DNA
Before the introduction of pDNA into the damaged 
ligaments, the liquid pDNA was warmed to +37°C. 
Then, 3.5 ml was injected directly into the damaged 
sites following the ultrasonic and aseptic conditions 
guidelines. Multi-injections were administered 
into the affected sites at a distance of 1 cm apart to 
ensure a uniformed and guaranteed distribution of the 
drug throughout the damaged tissues. For the entire 
treatment, just a single injection of the drug (pDNA) 
was used. Following drug administration, the wounded 
area was tightly covered with bandages and the horse 
was given strict rest for 2 days, and then step load 
exercise rehabilitation was prescribed for 3 weeks.
Ethical approval
All human standard guidelines established by the US 
Food and Drug Administration for safe administration 
(Food and Drug Administration, 2007; Content and 
Review of Chemistry, Manufacturing, and Control 
(CMC) Information for Human Somatic Cell Therapy 
Investigational New Drug Applications, 2008) and 
the Human Medicines Committee of the European 
Medicines Agency (European Medicines Agency, 
2011, 2015) were adhered to when designing the 
plasmid vectors. For the treatment phase, a horse with 
a naturally occurring injury was brought to a veterinary 
clinic at Kazan Hippodrome (an international equestrian 
center). Informed consent to administer a therapeutic 
drug was obtained from the owners. All procedures 
were carried out in accordance with the international, 
national, and institutional guidelines for the care and 
use of animals. The Institutional Review Board of the 
Kazan Federal University approved this study (under 
protocol No3; date 05/05/2015).
Results
Therapeutic efficacy and the regenerative effect of the 
drug (pDNA) on connective tissues were studied in a 
2-year-old pure-bred Arabian stallion with damage to 
the superficial extensor. During clinical examination, 
it was observed that the horse was limping on the left 
forelimb. The degree of lameness was rated 2 out of 5 
(according to the 5-point lameness scale (2) AAEP). 
The pronounced anechoic and hypoechoic zones at 
the back of the limb was visualized using ultrasound 
examination of the damaged leg (Fig. 1). A diagnosis 
of tendonitis of the superficial digital flexor was 
made.
On the 10th day after pDNA administration, clinical 
examination confirmed no lameness on the previously 
affected left forelimb. An ultrasound examination of the 
superficial digital flexor revealed increased echogenicity 
in the damaged area, indicating heterogeneity of the 
Fig. 1. Ultrasonography of the superficial digital flexor. (A): Before the introduction of plasmid 
DNA. (B): 20th day after the introduction of plasmid DNA.
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structure in the damaged area, due to the formation of 
connective tissue.
On the 20th day after drug administration, the absence 
of lameness and lack of swelling at the site of damage 
were observed. An ultrasound scan showed an increase 
in the degree of echogenicity and a decrease in the 
hypoechoic region of the damaged area (Fig. 1).
On the 50th day after administration of the drug, the 
absence of lameness was noted during the examination. 
Ultrasound examination showed a decrease in the 
hypoechoic zone, and an increase in echogenicity at the 
site of damage was also observed (Fig. 2).
On the 80th day, the absence of lameness was still 
observed. Ultrasound examination showed a decrease 
in the hypoechoic zone and an increase in echogenicity 
at the site of injury. This indicated the presence of a 
reparative process. As the clinical and ultrasound 
characteristics of the damaged tendon improved, a 
gradual introduction of trotting was prescribed in 
addition to walking.
Fig. 2. Ultrasonography of the superficial digital flexor. (C): 50th day after the introduction of plasmid 
DNA. (D): 80th day after the introduction of plasmid DNA.
Fig. 3. Ultrasonography of the superficial digital flexor. (E): 110th day after the introduction of plasmid 
DNA. (F): 140th day after the introduction of plasmid DNA.
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On the 110th day, after administration of the drug, 
the horse was examined again in the clinic. The 
examination showed the absence of lameness in the 
left thoracic limb when the horse was moving on hard 
and soft ground, during both walking steps and trotting. 
Ultrasound examination revealed that the structure 
of the superficial digital flexor was close to normal 
tendon tissue. The tendon structure was quite uniform 
throughout its length, and the sites of partial damage to 
the ligament were hardly seen.
On the 140th day, a decrease in the hypoechoic zone was 
observed during ultrasound examination. There was no 
swelling at the site of injury and clinical examination 
showed the absence of claudication. Also, the horse 
calmly rested on the injured leg. Furthermore, clinical 
data, as well as ultrasound examination, revealed the 
presence of regeneration processes on this day (Fig. 3).
On the 185th day, after clinical examination, 
deterioration of the damaged limb was observed. 
Ultrasound examination revealed no changes in the 
area of drug administration. However, a new lesion was 
discovered in this tendon.
On the 210th day, ultrasound revealed a significant 
increase in the hypoechoic zone in the new lesion. It 
also showed the presence of damage to the deep digital 
flexor tendon. Upon external examination, slight 
swelling and lameness were noted.
No adverse reactions to the drug or contaminations at 
the site of infection were noted at any point during the 
treatment process. 
Discussion
In dressage horses, the most common injuries occur in 
the digital flexor tendon and suspensory ligament due 
to extensive training and sporting activities causing 
orthopedic disorders. As a result, the performances 
of the horses are reduced which can lead to early 
retirement from competition, and in most cases, the 
traditional medications and regimes used to treat them 
still result in relapses of the injuries in later years. One 
of the significant problems with orthopedic disorders 
is the prevention of blood supply to the ischemic 
tissues in the injury area. Currently, one of the most 
promising approaches to the restoration of blood 
supply to ischemic tissues is gene therapy aimed at 
ensuring the growth of new blood vessels. Evidently, 
angiogenesis begins with the migration of endothelial 
cells into the intercellular space in the direction of the 
occluded vessel. The main molecular factors initiating 
and controlling this process are, to a greater extent, 
various types of VEGFs, and to a lesser extent, FGFs 
(Sylven, 2002). Thus, the transfer of genes of these 
factors into ischemic tissues can initiate local growth 
and development of blood vessels by overexpression 
of specific proteins. To make the gene therapy drug, 
we used the species-specific VEGF164 and FGF2 
genes. These genes encode proteins that promote the 
process of regeneration of both blood vessels and 
connective tissues in the equine. Also, VEGF164 in 
vivo stimulates angiogenesis by attracting endothelial 
progenitor cells from the bone marrow. In addition, 
it stabilizes newly formed vessels and increases their 
permeability at the site of damage, which contributes 
to the formation of granulation tissues (Litvin et al., 
2016). Correspondingly, FGF2 induces proliferation of 
cells, and regeneration of the nervous, muscular, and 
connective tissues. Growth factors VEGF and FGF2 
are known to be polypeptides that are mainly released 
by platelets, fibroblasts, and endothelial cells at the site 
of injury (Byrne et al., 2005). They are closely related 
to other factors of inflammation and regeneration. 
It is believed that they stimulate the migration of 
tendoblasts, fibroblasts, and mesenchymal stem cells, 
which are responsible for the production of collagen 
and other extracellular components of ligaments and 
tendons, such as proteoglycans, glycosaminoglycans, 
and glycoproteins, through enhanced angiogenesis 
(the process of formation of new vessels) at the site of 
damage (Martinek et al., 2005).
The in vivo efficacy of pBUDK-ecVEGF164-ecFGF 
pDNA was confirmed previously by us in the treatment 
of tendon injury of the superficial digital flexor 
(Kovac et al., 2017). Treatment with gene therapy led 
to a significant improvement in the condition of the 
animal. Three months after the introduction of pDNA 
encoding VEGF and FGF2 genes, the damaged tendon 
regenerated. Dynamic ultrasound examinations at the 
damaged tendon area of the superficial digital flexor 
showed a significant decrease in the hypoechoic region. 
During this period, the horse was released for training and 
it was planned that the animal would be introduced into 
normal sports mode load after three months. However, 
two months after the start of training, the animal began 
to limp and new but separate damage to the tendon of 
the superficial digital flexor was discovered. According 
to an ultrasound scan, the new lesion was located above 
the area that had been successfully restored using gene 
therapy. We believe that damage to the intact tendon 
during training occurred as a result of microtrauma 
received as a result of past competitions and not due to 
the recovery after the gene therapy. This suggests that 
gene therapy treatment has a pronounced therapeutic 
effect with high efficiency. However, to confirm this 
hypothesis, a histological and immunohistochemical 
study of biopsy materials obtained from a damaged 
tendon is required. It is also necessary to be familiar 
with the causes of relapses in tendon injuries when 
applying gene therapy methods.
Currently, gene therapy is the most promising method 
of treatment in regenerative medicine. This opens 
up wide possibilities for its use in the treatment of 
orthopedic pathology, in particular for the treatment of 
damaged ligaments and tendons (Martinek et al., 2005; 
Evans et al., 2009; Tang et al., 2016).
Gene therapy as a novel method for the treatment of 
orthopedic disorders has been actively used not only 
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in horses (Kovac et al., 2017; 2018), but also in other 
animals and humans (Plotnikov et al., 2012; Zakirova 
et al., 2014). The application of a construct plasmid 
encoding the VEGF164 and BMP2 genes to treat the 
damage to the anterior cruciate ligament in a dog was 
previously described (Kovac et al., 2018). Also, gene 
therapy was used for the treatment of lower limb 
ischemia in humans. In all these treatments, the use 
of genetic contracts has proved efficiency and safety 
(Plotnikov et al., 2012; Deev et al., 2015; 2017). 
Thus, this study shows that the introduction of pDNA 
encoding specie-specific VEGF164 and FGF2 genes 
increased the regenerative activities of the damaged 
tendon. However, it is necessary to be more careful 
about horse training, since the possibility of damage 
to other parts of the treated tendon cannot be ruled 
out. Although there are many challenges in the use 
of gene therapy, this study shows the therapeutic 
properties of genetic constructs (pDNA) and 
contribute to the advancements in the use of these 
therapies.
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